MedPath

Effect of vitamin B12 in treatment of fatty liver disease

Phase 3
Conditions
on-alcoholic fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0
Registration Number
IRCT20120718010333N5
Lead Sponsor
Kashan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Patients who are diagnosed to have non alcoholic fatty liver disease confirmed with ultrasonography result
Ages between 18-80 years
Serum alanine transaminase enzyme level higher than 30 U/L in men
Serum alanine transaminase enzyme level higher than 19 U/L in women

Exclusion Criteria

Pregnancy
Lactation
Alcohol consumption greater than 20 g per day
Having diseases such as hereditary hemochromatosis, Wilson's disease and a1 antitripsin enzyme deficiency
History of jejunoileal bypass surgery or gastroplasty
History of receiving total parenteral nutrition during last 6 months
Consumption of statins and hepatotoxic drugs such as calcium channel blocker, methotrexate, amiodarone, chloroquine
History of hypothyroidism and Cushing's syndrome
Intake of folate, B12, vitamin E and omega-3 supplements during the last 3 months

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath